

Bruno Sangro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4395983/publications.pdf>

Version: 2024-02-01

257
papers

26,936
citations

9264

74
h-index

6996

154
g-index

268
all docs

268
docs citations

268
times ranked

20431
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. <i>Lancet, The</i> , 2017, 389, 2492-2502.	13.7	3,224
2	Hepatocellular carcinoma. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16018.	30.5	1,863
3	Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approachâ€”The ALBI Grade. <i>Journal of Clinical Oncology</i> , 2015, 33, 550-558.	1.6	1,810
4	BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. <i>Journal of Hepatology</i> , 2022, 76, 681-693.	3.7	1,495
5	Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. <i>Journal of Hepatology</i> , 2016, 65, 719-726.	3.7	883
6	A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 81-88.	3.7	816
7	Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib. <i>JAMA Oncology</i> , 2020, 6, e204564.	7.1	746
8	Advances in immunotherapy for hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 525-543.	17.8	609
9	Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. <i>Hepatology</i> , 2011, 54, 868-878.	7.3	550
10	Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2022, 23, 77-90.	10.7	526
11	Heterogeneity of Patients with Intermediate (BCLC B) Hepatocellular Carcinoma: Proposal for a Subclassification to Facilitate Treatment Decisions. <i>Seminars in Liver Disease</i> , 2013, 32, 348-359.	3.6	508
12	Immunological landscape and immunotherapy of hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2015, 12, 681-700.	17.8	478
13	Liver disease induced by radioembolization of liver tumors. <i>Cancer</i> , 2008, 112, 1538-1546.	4.1	330
14	Phase I Trial of Intratumoral Injection of an Adenovirus Encoding Interleukin-12 for Advanced Digestive Tumors. <i>Journal of Clinical Oncology</i> , 2004, 22, 1389-1397.	1.6	295
15	Radioembolization for hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2012, 56, 464-473.	3.7	268
16	Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 2991-3001.	1.6	257
17	Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, 1460-1469.	3.7	254
18	Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 1164-1174.	3.7	249

#	ARTICLE	IF	CITATIONS
19	Prognostic factors and prevention of radioembolization-induced liver disease. <i>Hepatology</i> , 2013, 57, 1078-1087.	7.3	240
20	Treatment Parameters and Outcome in 680 Treatments of Internal Radiation With Resin 90Y-Microspheres for Unresectable Hepatic Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1494-1500.	0.8	238
21	Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.. <i>Journal of Clinical Oncology</i> , 2022, 40, 379-379.	1.6	235
22	Systemic treatment of hepatocellular carcinoma: An EASL position paper. <i>Journal of Hepatology</i> , 2021, 75, 960-974.	3.7	217
23	Positron Emission Tomography Imaging of Adenoviral-Mediated Transgene Expression in Liver Cancer Patients. <i>Gastroenterology</i> , 2005, 128, 1787-1795.	1.3	211
24	Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 792-800.	0.8	207
25	Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tissue Origins. <i>Clinical Cancer Research</i> , 2014, 20, 5697-5707.	7.0	200
26	Immunotherapy of Hepatocellular Carcinoma: Facts and Hopes. <i>Clinical Cancer Research</i> , 2018, 24, 1518-1524.	7.0	194
27	Patient Selection and Activity Planning Guide for Selective Internal Radiotherapy With Yttrium-90 Resin Microspheres. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 401-407.	0.8	190
28	Research Reporting Standards for Radioembolization of Hepatic Malignancies. <i>Journal of Vascular and Interventional Radiology</i> , 2011, 22, 265-278.	0.5	185
29	Influence of tumor characteristics on the outcome of liver transplantation among patients with liver cirrhosis and hepatocellular carcinoma. <i>Liver Transplantation</i> , 2001, 7, 631-636.	2.4	184
30	A multidrug resistance 3 gene mutation causing cholelithiasis, cholestasis of pregnancy, and adulthood biliary cirrhosis. <i>Gastroenterology</i> , 2003, 124, 1037-1042.	1.3	183
31	Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4012-4012.	1.6	178
32	Intratumoral Injection of Dendritic Cells Engineered to Secrete Interleukin-12 by Recombinant Adenovirus in Patients With Metastatic Gastrointestinal Carcinomas. <i>Journal of Clinical Oncology</i> , 2005, 23, 999-1010.	1.6	170
33	Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 72, 320-341.	3.7	165
34	Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. <i>Hepatology</i> , 2013, 58, 2188-2197.	7.3	154
35	Long-term impact of liver function on curative therapy for hepatocellular carcinoma: application of the ALBI grade. <i>British Journal of Cancer</i> , 2016, 114, 744-750.	6.4	150
36	Partial splenic embolization for the treatment of hypersplenism in cirrhosis. <i>Hepatology</i> , 1993, 18, 309-314.	7.3	148

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. <i>Liver Transplantation</i> , 2012, 18, 45-52.	2.4	143
38	International recommendations for personalised selective internal radiation therapy of primary and metastatic liver diseases with yttrium-90 resin microspheres. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 1570-1584.	6.4	140
39	Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. <i>Hepatology</i> , 2001, 33, 52-61.	7.3	139
40	De Novo neoplasia after liver transplantation: An analysis of risk factors and influence on survival. <i>Liver Transplantation</i> , 2005, 11, 89-97.	2.4	139
41	Radioembolization with Use of Yttrium-90 Resin Microspheres in Patients with Hepatocellular Carcinoma and Portal Vein Thrombosis. <i>Journal of Vascular and Interventional Radiology</i> , 2010, 21, 1205-1212.	0.5	136
42	Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90. <i>Oncology</i> , 2013, 84, 311-318.	1.9	134
43	Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4073-4073.	1.6	133
44	Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 1715-1721.	3.9	132
45	Hepatitis B and C viral infections in patients with hepatocellular carcinoma. <i>Hepatology</i> , 1992, 16, 637-641.	7.3	129
46	Targets for immunotherapy of liver cancer. <i>Journal of Hepatology</i> , 2018, 68, 157-166.	3.7	129
47	Gastroduodenal Injury After Radioembolization of Hepatic Tumors. <i>American Journal of Gastroenterology</i> , 2007, 102, 1216-1220.	0.4	128
48	Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. <i>Liver Transplantation</i> , 2008, 14, 272-278.	2.4	128
49	CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 600-609.	3.7	127
50	The Role of Thrombopoietin in the Thrombocytopenia of Patients with Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 2005, 100, 1311-1316.	0.4	122
51	Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria. <i>Journal of Hepatology</i> , 2016, 65, 776-783.	3.7	119
52	Radioembolization for the Treatment of Liver Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 91-99.	1.3	118
53	Dendritic cells delivered inside human carcinomas are sequestered by interleukin-8. <i>International Journal of Cancer</i> , 2005, 116, 275-281.	5.1	112
54	Serum Metabolites as Diagnostic Biomarkers for Cholangiocarcinoma, Hepatocellular Carcinoma, and Primary Sclerosing Cholangitis. <i>Hepatology</i> , 2019, 70, 547-562.	7.3	112

#	ARTICLE	IF	CITATIONS
55	Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. <i>Liver Transplantation</i> , 1999, 5, 414-420.	1.8	107
56	Liver Transplant Recipients Older Than 60 Years Have Lower Survival and Higher Incidence of Malignancy. <i>American Journal of Transplantation</i> , 2003, 3, 1407-1412.	4.7	105
57	A phase I clinical trial of thymidine kinase-based gene therapy in advanced hepatocellular carcinoma. <i>Cancer Gene Therapy</i> , 2010, 17, 837-843.	4.6	103
58	Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 379-393.	4.2	100
59	Prevention and treatment of complications of selective internal radiation therapy: Expert guidance and systematic review. <i>Hepatology</i> , 2017, 66, 969-982.	7.3	99
60	Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: Results of a pilot randomized controlled clinical trial. <i>Journal of Hepatology</i> , 2005, 43, 630-636.	3.7	97
61	Nivolumab (NIVO) + ipilimumab (IPI) + cabozantinib (CABO) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.. <i>Journal of Clinical Oncology</i> , 2020, 38, 478-478.	1.6	93
62	Combined Immunostimulatory Monoclonal Antibodies Extend Survival in an Aggressive Transgenic Hepatocellular Carcinoma Mouse Model. <i>Clinical Cancer Research</i> , 2013, 19, 6151-6162.	7.0	92
63	Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach. <i>Hepatology</i> , 2020, 72, 198-212.	7.3	92
64	Radioembolization for Hepatocellular Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 422-431.	1.3	91
65	Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: The effect of smoking withdrawal. <i>Liver Transplantation</i> , 2011, 17, 402-408.	2.4	89
66	Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance. <i>Liver Transplantation</i> , 2013, 19, 937-944.	2.4	87
67	Prolonged and inducible transgene expression in the liver using gutless adenovirus: A potential therapy for liver cancer. <i>Gastroenterology</i> , 2004, 126, 278-289.	1.3	86
68	Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 4508-4508.	1.6	86
69	Gene Therapy of Cancer Based on Interleukin 12. <i>Current Gene Therapy</i> , 2005, 5, 573-581.	2.0	85
70	Nonmelanoma skin cancer after liver transplantation. Study of risk factors. <i>Liver Transplantation</i> , 2005, 11, 1100-1106.	2.4	82
71	Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2013, 59, 753-761.	3.7	82
72	Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.. <i>Journal of Clinical Oncology</i> , 2019, 37, 327-327.	1.6	80

#	ARTICLE	IF	CITATIONS
73	Herpes zoster after liver transplantation: Incidence, risk factors, and complications. Liver Transplantation, 2004, 10, 1140-1143.	2.4	76
74	Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.. Journal of Clinical Oncology, 2017, 35, 4013-4013.	1.6	76
75	Gene Transfer and Therapy with Adenoviral Vector in Rats with Diethylnitrosamine-Induced Hepatocellular Carcinoma. Human Gene Therapy, 1997, 8, 349-358.	2.7	75
76	Biocompatibility, Inflammatory Response, and Recanalization Characteristics of Nonradioactive Resin Microspheres: Histological Findings. CardioVascular and Interventional Radiology, 2009, 32, 727-736.	2.0	74
77	Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial <scp>SORAMIC</scp>. Liver International, 2015, 35, 620-626.	3.9	74
78	General Selection Criteria of Patients for Radioembolization of Liver Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 337-341.	1.3	72
79	The search for novel diagnostic and prognostic biomarkers in cholangiocarcinoma. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 1468-1477.	3.8	72
80	Transarterial Chemoembolization and Radioembolization. Seminars in Liver Disease, 2014, 34, 435-443.	3.6	71
81	Spontaneous regression of hepatocellular carcinoma: a systematic review. European Journal of Gastroenterology and Hepatology, 2009, 21, 254-257.	1.6	69
82	Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension. Hpb, 2014, 16, 243-249.	0.3	69
83	Medical treatment for cholangiocarcinoma. Liver International, 2019, 39, 123-142.	3.9	69
84	Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection. Journal of Hepatology, 2011, 54, 422-431.	3.7	68
85	Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules. Journal of Hepatology, 2019, 70, 874-884.	3.7	67
86	Transarterial chemo-embolisation of hepatocellular carcinoma: impact of liver function and vascular invasion. British Journal of Cancer, 2017, 116, 448-454.	6.4	66
87	Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2010, 22, 391-398.	1.6	60
88	Pilot Clinical Trial of Type 1 Dendritic Cells Loaded with Autologous Tumor Lysates Combined with GM-CSF, Pegylated IFN, and Cyclophosphamide for Metastatic Cancer Patients. Journal of Immunology, 2011, 187, 6130-6142.	0.8	59
89	Comparative Study of Four Different Spherical Embolic Particles in an Animal Model: A Morphologic and Histologic Evaluation. Journal of Vascular and Interventional Radiology, 2008, 19, 1625-1638.	0.5	58
90	Prognosis of hepatocellular carcinoma in relation to treatment: A multivariate analysis of 178 patients from a single European institution. Surgery, 1998, 124, 575-583.	1.9	57

#	ARTICLE	IF	CITATIONS
91	Safety and Efficacy Assessment of Flow Redistribution by Occlusion of Intrahepatic Vessels Prior to Radioembolization in the Treatment of Liver Tumors. <i>CardioVascular and Interventional Radiology</i> , 2010, 33, 523-531.	2.0	56
92	Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation. <i>Liver International</i> , 2015, 35, 1590-1596.	3.9	55
93	Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. <i>Hepatology</i> , 2018, 67, 612-622.	7.3	55
94	Analysis of Prognostic Factors After Yttrium-90 Radioembolization of Advanced Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 1441-1448.	0.8	54
95	Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 7315-7321.	2.0	54
96	Prognosis of Hepatocellular Carcinoma in Relation to Treatment Across BCLC Stages. <i>Annals of Surgical Oncology</i> , 2011, 18, 1964-1971.	1.5	53
97	Splicing events in the control of genome integrity: role of SLU7 and truncated SRSF3 proteins. <i>Nucleic Acids Research</i> , 2019, 47, 3450-3466.	14.5	53
98	A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib. <i>Liver International</i> , 2016, 36, 1206-1212.	3.9	52
99	Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab + Bevacizumab Treatment of Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 3537-3545.	7.0	52
100	Usefulness of a program of neoplasia surveillance in liver transplantation. A preliminary report. <i>Clinical Transplantation</i> , 2009, 23, 532-536.	1.6	51
101	Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT). <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 21-35.	2.0	49
102	Plasma levels of substance p in liver cirrhosis: Relationship to the activation of vasopressor systems and urinary sodium excretion. <i>Hepatology</i> , 1995, 21, 35-40.	7.3	47
103	Spontaneous Regression of Hepatocellular Carcinoma: Three Case Reports and a Categorized Review of the Literature. <i>Digestive Diseases and Sciences</i> , 2009, 54, 1147-1153.	2.3	47
104	Liver transplantation in cirrhotic patients with diabetes mellitus: Midterm results, survival, and adverse events. <i>Liver Transplantation</i> , 2001, 7, 226-233.	2.4	46
105	Wilms' Tumor 1 Gene Expression in Hepatocellular Carcinoma Promotes Cell Dedifferentiation and Resistance to Chemotherapy. <i>Cancer Research</i> , 2009, 69, 1358-1367.	0.9	46
106	Totally Laparoscopic Right Hepatectomy for Living Donor Liver Transplantation: Analysis of a Preliminary Experience on 5 Consecutive Cases. <i>Transplantation</i> , 2017, 101, 548-554.	1.0	46
107	Prospective Randomized Trial of Enoxaparin, Pentoxifylline and Ursodeoxycholic Acid for Prevention of Radiation-Induced Liver Toxicity. <i>PLoS ONE</i> , 2014, 9, e112731.	2.5	46
108	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma. , 2021, 9, e002794.		43

#	ARTICLE	IF	CITATIONS
109	Deregulation of <i>linc-PINT</i> in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells. <i>Oncotarget</i> , 2018, 9, 12842-12852.	1.8	43
110	The Post-SIR-Spheres Surgery Study (P4S): Retrospective Analysis of Safety Following Hepatic Resection or Transplantation in Patients Previously Treated with Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres. <i>Annals of Surgical Oncology</i> , 2017, 24, 2465-2473.	1.5	42
111	Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib. <i>Oncotarget</i> , 2017, 8, 103077-103086.	1.8	41
112	Liver Failure Caused by Herpes Simplex Virus Thymidine Kinase Plus Ganciclovir Therapy Is Associated with Mitochondrial Dysfunction and Mitochondrial DNA Depletion. <i>Human Gene Therapy</i> , 2003, 14, 463-472.	2.7	40
113	Radioembolization in the Treatment of Unresectable Liver Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 167-177.	1.3	40
114	Milestones in the pathogenesis and management of primary liver cancer. <i>Journal of Hepatology</i> , 2020, 72, 209-214.	3.7	39
115	Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): Subanalyses of CheckMate-040.. <i>Journal of Clinical Oncology</i> , 2018, 36, 475-475.	1.6	39
116	Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues. <i>Cancer Research</i> , 2019, 79, 5167-5180.	0.9	38
117	Assessing the impact of COVID-19 on liver cancer management (CERO-19). <i>JHEP Reports</i> , 2021, 3, 100260.	4.9	36
118	Liver Damage using Suicide Genes. <i>American Journal of Pathology</i> , 2000, 157, 549-559.	3.8	35
119	Safety of selective internal radiation therapy (SIRT) with yttrium-90 microspheres combined with systemic anticancer agents: expert consensus. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 1079-1099.	1.4	34
120	A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma. <i>Hepato-Gastroenterology</i> , 2009, 56, 1683-8.	0.5	33
121	Transarterial therapies for hepatocellular carcinoma. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1057-1073.	1.8	32
122	Prognostic model for early acute rejection after liver transplantation. <i>Liver Transplantation</i> , 2001, 7, 246-254.	2.4	31
123	Efficacy and Toxicity of Intra-Arterial Cisplatin and Etoposide for Advanced Hepatocellular Carcinoma. <i>Oncology</i> , 2002, 62, 293-298.	1.9	31
124	Gene therapy of liver diseases. <i>Expert Opinion on Biological Therapy</i> , 2004, 4, 1073-1091.	3.1	31
125	Integrating Radioembolization into the Treatment Paradigm for Metastatic Neuroendocrine Tumors in the Liver. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 393-398.	1.3	31
126	Phase I/II Multicenter Trial of a Novel Therapeutic Cancer Vaccine, HepaVac-101, for Hepatocellular Carcinoma. <i>Clinical Cancer Research</i> , 2022, 28, 2555-2566.	7.0	31

#	ARTICLE	IF	CITATIONS
127	Tracing Transgene Expression in Cancer Gene Therapy a Requirement for Rational Progress in the Field. <i>Molecular Imaging and Biology</i> , 2002, 4, 27-33.	2.6	30
128	Treatment of Hepatocellular Carcinoma by Radioembolization Using ⁹⁰ Y Microspheres. <i>Digestive Diseases</i> , 2009, 27, 164-169.	1.9	30
129	Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma. <i>Cancer Research</i> , 2021, 81, 4910-4925.	0.9	30
130	Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA101-LBA101.	1.6	29
131	NatB-mediated protein N-terminal acetylation is a potential therapeutic target in hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 40967-40981.	1.8	29
132	Positron emission tomography and gene therapy: basic concepts and experimental approaches for gene expression imaging. <i>Molecular Imaging and Biology</i> , 2004, 6, 225-238.	2.6	28
133	Phase 1 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow-derived endothelial progenitor cells. <i>Translational Research</i> , 2017, 188, 80-91.e2.	5.0	28
134	Gene therapy of liver cancer. <i>World Journal of Gastroenterology</i> , 2006, 12, 6085.	3.3	27
135	Liver cancer arterial perfusion modelling and CFD boundary conditions methodology: a case study of the haemodynamics of a patient-specific hepatic artery in literature-based healthy and tumour-bearing liver scenarios. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2016, 32, e02764.	2.1	26
136	Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them. <i>Journal of Hepatology</i> , 2017, 66, 1114-1117.	3.7	26
137	Risk factors for recurrence of hepatitis C after liver transplantation. <i>Liver Transplantation</i> , 1998, 4, 265-270.	1.8	25
138	Immune monitoring of immunosuppression withdrawal of liver transplant recipients. <i>Transplant Immunology</i> , 2015, 33, 110-116.	1.2	25
139	Factors related to increased resting energy expenditure in men with liver cirrhosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 139-145.	1.6	25
140	Effectiveness of Aprotinin in Orthotopic Liver Transplantation. <i>Seminars in Thrombosis and Hemostasis</i> , 1993, 19, 292-296.	2.7	22
141	Gene therapy of liver cancer. <i>Annals of Hepatology</i> , 2007, 6, 5-14.	1.5	22
142	Integrating Radioembolization (90Y Microspheres) Into Current Treatment Options for Liver Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 81-90.	1.3	22
143	Liver function after combined selective internal radiation therapy or sorafenib monotherapy in advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2021, 75, 1387-1396.	3.7	22
144	Long-term follow-up study of gastroduodenal lesions after radioembolization of hepatic tumors. <i>World Journal of Gastroenterology</i> , 2013, 19, 2935-2940.	3.3	22

#	ARTICLE	IF	CITATIONS
145	Integrating Radioembolization With Chemotherapy in the Treatment Paradigm for Unresectable Colorectal Liver Metastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2012, 35, 293-301.	1.3	21
146	Agenesis of the dorsal pancreas: systematic review of a clinical challenge. <i>Revista Espanola De Enfermedades Digestivas</i> , 2016, 108, 000-000.	0.3	21
147	Hyperhomocysteinemia in Liver Transplant Recipients: Prevalence and Multivariate Analysis of Predisposing Factors. <i>Liver Transplantation</i> , 2000, 6, 614-618.	2.4	20
148	Radiological response to nivolumab in patients with hepatocellular carcinoma: A multicenter analysis of real-life practice. <i>European Journal of Radiology</i> , 2021, 135, 109484.	2.6	20
149	Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation. <i>Annals of Transplantation</i> , 2017, 22, 141-147.	0.9	20
150	Gene Therapy of Hepatocellular Carcinoma. <i>Digestive Diseases</i> , 2001, 19, 324-332.	1.9	19
151	A signature of six genes highlights defects on cell growth and specific metabolic pathways in murine and human hepatocellular carcinoma. <i>Functional and Integrative Genomics</i> , 2011, 11, 419-429.	3.5	19
152	Chemoembolization and radioembolization. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2014, 28, 909-919.	2.4	19
153	Computational particleâ€œhaemodynamics analysis of liver radioembolization pretreatment as an actual treatment surrogate. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2017, 33, e02791.	2.1	19
154	Is a Technetium-99m Macroaggregated Albumin Scan Essential in the Workup for Selective Internal Radiation Therapy with Yttrium-90? An Analysis of 532 Patients. <i>Journal of Vascular and Interventional Radiology</i> , 2017, 28, 1536-1542.	0.5	19
155	The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer. , 2016, 4, .		18
156	Radioembolisation in patients with hepatocellular carcinoma that have previously received liver-directed therapies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1721-1730.	6.4	18
157	The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. <i>Cancers</i> , 2021, 13, 2651.	3.7	18
158	Gene therapy of neoplastic liver diseases. <i>International Journal of Biochemistry and Cell Biology</i> , 2003, 35, 135-148.	2.8	17
159	Gene Therapy of Hepatocellular Carcinoma and Gastrointestinal Tumors. <i>Annals of the New York Academy of Sciences</i> , 2002, 963, 6-12.	3.8	17
160	Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?. <i>Immunotherapy</i> , 2009, 1, 845-853.	2.0	17
161	Computational assessment of the effects of the catheter type on particleâ€œhemodynamics during liver radioembolization. <i>Journal of Biomechanics</i> , 2016, 49, 3705-3713.	2.1	17
162	Cold-Inducible RNA Binding Protein as a Vaccination Platform to Enhance Immunotherapeutic Responses against Hepatocellular Carcinoma. <i>Cancers</i> , 2020, 12, 3397.	3.7	17

#	ARTICLE	IF	CITATIONS
163	Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes <i>in vitro</i> and <i>in vivo</i> . <i>International Journal of Cancer</i> , 2011, 129, 374-386.	5.1	16
164	Assessment of the Hong Kong Liver Cancer Staging System in Europe. <i>Liver International</i> , 2016, 36, 911-917.	3.9	16
165	Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH. <i>Medicina Clínica (English Edition)</i> , 2021, 156, 463.e1-463.e30.	0.2	16
166	Neoantigens as potential vaccines in hepatocellular carcinoma. , 2022, 10, e003978.		16
167	Idiopathic adulthood ductopenia: long-term follow-up after liver transplantation. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1420-1423.	2.3	15
168	New strategies to enhance gene therapy efficiency. <i>Gastroenterology</i> , 2002, 123, 639-642.	1.3	15
169	Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection. <i>Molecular Therapy - Methods and Clinical Development</i> , 2015, 2, 15006.	4.1	15
170	The role of angled-tip microcatheter and microsphere injection velocity in liver radioembolization: A computational particle-hemodynamics study. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2017, 33, e2895.	2.1	15
171	International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis. <i>Liver International</i> , 2020, 40, 1467-1476.	3.9	15
172	Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. <i>CardioVascular and Interventional Radiology</i> , 2021, 44, 36-49.	2.0	15
173	PARTIAL SPLENIC EMBOLIZATION IN THE TREATMENT OF THROMBOCYTOPENIA AFTER LIVER TRANSPLANTATION. <i>Transplantation</i> , 1997, 63, 482-484.	1.0	15
174	Liver Radioembolization: An Analysis of Parameters that Influence the Catheter-Based Particle-Delivery via CFD. <i>Current Medicinal Chemistry</i> , 2020, 27, 1600-1615.	2.4	15
175	Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters*1. <i>Hepatology</i> , 1995, 21, 986-994.	7.3	14
176	Treatment of murine fulminant hepatitis with genetically engineered endothelial progenitor cells. <i>Journal of Hepatology</i> , 2011, 55, 828-837.	3.7	14
177	Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial. <i>Clinical Cancer Research</i> , 2022, 28, 3890-3901.	7.0	14
178	Nonsurgical Treatment for Localized Hepatocellular Carcinoma. <i>Current Oncology Reports</i> , 2014, 16, 373.	4.0	13
179	The Treatment of Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020, 40, 174-185.	3.8	13
180	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 475-485.	2.5	13

#	ARTICLE	IF	CITATIONS
181	Computational Fluid Dynamics Modeling of Liver Radioembolization: A Review. CardioVascular and Interventional Radiology, 2022, 45, 12-20.	2.0	13
182	Renal Biopsy with Forceps through the Femoral Vein. Journal of Vascular and Interventional Radiology, 1995, 6, 641-645.	0.5	12
183	Numerical investigation of liver radioembolization via computational particleâ€hemodynamics: The role of the microcatheter distal direction and microsphere injection point and velocity. Journal of Biomechanics, 2016, 49, 3714-3721.	2.1	12
184	A proof-of-concept study of the in-vivo validation of a computational fluid dynamics model of personalized radioembolization. Scientific Reports, 2021, 11, 3895.	3.3	12
185	3D voxel-based dosimetry to predict contralateral hypertrophy and an adequate future liver remnant after lobar radioembolization. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 3048-3057.	6.4	12
186	Gene therapy for liver cancer: clinical experience and future prospects. Current Opinion in Molecular Therapeutics, 2010, 12, 561-9.	2.8	12
187	Physiological outflow boundary conditions methodology for small arteries with multiple outlets: A patient-specific hepatic artery haemodynamics case study. Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, 2015, 229, 291-306.	1.8	11
188	Numerical zeroâ€dimensional hepatic artery hemodynamics model for balloonâ€occluded transarterial chemoembolization. International Journal for Numerical Methods in Biomedical Engineering, 2018, 34, e2983.	2.1	11
189	Effectiveness of lamivudine in treatment of acute recurrent hepatitis B after liver transplantation. Digestive Diseases and Sciences, 1998, 43, 1186-1189.	2.3	10
190	Refined tools for the treatment of hepatocellular carcinoma. Journal of Hepatology, 2005, 42, 629-631.	3.7	10
191	Recommendations for SIR-Spheres Y-90 resin microspheres in chemotherapy-refractory/intolerant colorectal liver metastases. Future Oncology, 2017, 13, 2065-2082.	2.4	10
192	Future therapies for hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2005, 17, 515-521.	1.6	9
193	Liver Radioembolization Using ⁹⁰ Y Resin Microspheres in Elderly Patients: Tolerance and Outcome. Hospital Practice (1995), 2010, 38, 103-109.	1.0	8
194	Recommendations for radioembolisation after liver surgery using yttrium-90 resin microspheres based on a survey of an international expert panel. European Radiology, 2017, 27, 4923-4930.	4.5	8
195	Selective Internal Radiation Therapy Approval for Early HCC: What Comes Next?. Hepatology, 2021, 74, 2333-2335.	7.3	8
196	Clinical Application of Radioembolization in Hepatic Malignancies: Protocol for a Prospective Multicenter Observational Study. JMIR Research Protocols, 2020, 9, e16296.	1.0	8
197	Biologic therapy of liver tumors. Surgical Clinics of North America, 2004, 84, 673-696.	1.5	7
198	Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 661-668.	6.4	7

#	ARTICLE	IF	CITATIONS
199	Prognostic value of baseline interleukin 6 levels in liver decompensation and survival in HCC patients undergoing radioembolization. <i>EJNMMI Research</i> , 2021, 11, 51.	2.5	7
200	Splenic embolization prior to myelosuppressive treatment in hepatocarcinoma and active chronic hepatitis. <i>European Journal of Radiology</i> , 1992, 15, 211-214.	2.6	6
201	Identification of neoantigen-reactive T cells in hepatocellular carcinoma: implication in adoptive T cell therapy. <i>Journal of Hepatology</i> , 2020, 73, S39-S40.	3.7	6
202	The Pattern of Progression Defines Post-progression Survival in Patients with Hepatocellular Carcinoma Treated with SIRT. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 1165-1172.	2.0	6
203	Long Noncoding RNA EGOT Responds to Stress Signals to Regulate Cell Inflammation and Growth. <i>Journal of Immunology</i> , 2021, 206, 1932-1942.	0.8	6
204	A Real-World Observational Cohort of Patients with Hepatocellular Carcinoma: Design and Rationale for TARGET-1. <i>Hepatology Communications</i> , 2021, 5, 538-547.	4.3	6
205	Immunotherapies for hepatocellular carcinoma and intrahepatic cholangiocarcinoma: Current and developing strategies. <i>Advances in Cancer Research</i> , 2022, , 367-413.	5.0	6
206	Transvenous Liver Biopsy in Patients with Cirrhosis with Use of the Femoral Venous Approach and a Flexible Forceps. <i>Journal of Vascular and Interventional Radiology</i> , 1994, 5, 460-462.	0.5	5
207	Cytokines for the treatment of gastrointestinal cancers: clinical experience and new perspectives. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 827-841.	4.1	5
208	Zolmitriptan: A Novel Portal Hypotensive Agent Which Synergizes with Propranolol in Lowering Portal Pressure. <i>PLoS ONE</i> , 2013, 8, e52683.	2.5	5
209	Immunotherapy of hepatocellular carcinoma. <i>Hepatic Oncology</i> , 2014, 1, 433-446.	4.2	5
210	The joint use of ^{99m} Tc-MAA-SPECT/CT and cone-beam CT optimizes radioembolization planning. <i>EJNMMI Research</i> , 2021, 11, 23.	2.5	5
211	CFD Simulations of Radioembolization: A Proof-of-Concept Study on the Impact of the Hepatic Artery Tree Truncation. <i>Mathematics</i> , 2021, 9, 839.	2.2	5
212	DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis. <i>Cancers</i> , 2022, 14, 2048.	3.7	5
213	Reply to: "Pre-therapeutic dosimetry evaluation and selective internal radiation therapy of hepatocellular carcinoma using yttrium-90-loaded microspheres". <i>Journal of Hepatology</i> , 2013, 58, 1056-1057.	3.7	4
214	Stakeholder perspectives on European priorities for comprehensive liver cancer control: a conjoint analysis. <i>European Journal of Public Health</i> , 2013, 23, 951-957.	0.3	4
215	FRI-499-Efficacy and hepatic safety of nivolumab treatment in patients with Child-Pugh B disease and advanced hepatocellular carcinoma in CheckMate 040. <i>Journal of Hepatology</i> , 2019, 70, e619.	3.7	4
216	A methodology for numerically analysing the hepatic artery haemodynamics during B-TACE: a proof of concept. <i>Computer Methods in Biomechanics and Biomedical Engineering</i> , 2019, 22, 518-532.	1.6	4

#	ARTICLE	IF	CITATIONS
217	Monitoring one-carbon metabolism by mass spectrometry to assess liver function and disease. <i>Journal of Physiology and Biochemistry</i> , 2022, 78, 229-243.	3.0	4
218	Analysis of the albuminâ€bilirubin score as an indicator of improved liver function among hepatitis C virus patients with sustained viral response after direct-acting antiviral therapy. <i>JGH Open</i> , 2022, 6, 496-502.	1.6	4
219	On the importance of spiralâ€flow inflow boundary conditions when using idealized artery geometries in the analysis of liver radioembolization: A parametric study. <i>International Journal for Numerical Methods in Biomedical Engineering</i> , 2020, 36, e3337.	2.1	3
220	A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with Selective Internal Radiation Therapy. <i>Digestive Diseases</i> , 2022, 40, 322-334.	1.9	3
221	Pneumatocele during sorafenib therapy: first report of an unusual complication. <i>Oncotarget</i> , 2018, 9, 6652-6656.	1.8	3
222	Immunotherapy for patients with hepatocellular carcinoma and chronic viral infections. <i>Journal of Hepatology</i> , 2021, , .	3.7	3
223	A new animal model of atrophyâ€hypertrophy complex and liver damage following Yttrium-90 lobar selective internal radiation therapy in rabbits. <i>Scientific Reports</i> , 2022, 12, 1777.	3.3	3
224	Laparotomic eventration or colonic prolapse after chemotherapy-induced emesis. <i>Journal of Surgical Oncology</i> , 1988, 37, 204-206.	1.7	2
225	Pneumatosis coli due to pharmacological constipation. <i>Gastrointestinal Endoscopy</i> , 2007, 65, 710-711.	1.0	2
226	The ENRY analysis: a 325-patient European multicentre analysis. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 23-26.	2.2	2
227	Results in Hepatocellular Carcinoma. <i>Medical Radiology</i> , 2013, , 105-117.	0.1	2
228	Diagnosis and treatment of hepatocellular carcinoma. Update consensus document from the AEEH, SEOM, SERAM, SERVEI and SETH. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 511.e1-511.e22.	0.2	2
229	Radioembolization for hepatocellular carcinoma: gaining insight on a personalized approach. <i>Liver International</i> , 2017, 37, 32-34.	3.9	2
230	Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors. <i>Hepatic Oncology</i> , 2018, 5, HEP09.	4.2	2
231	Segmental Pneumonitis after Radioembolization. <i>Journal of Vascular and Interventional Radiology</i> , 2018, 29, 1305-1306.	0.5	2
232	Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know. <i>CardioVascular and Interventional Radiology</i> , 2019, 42, 1262-1270.	2.0	2
233	The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation. <i>Nucleic Acids Research</i> , 2021, 49, 8592-8609.	14.5	2
234	Radioembolisation in Hepatocellular Carcinoma: Principles of Management. , 2019, , 139-152.		2

#	ARTICLE	IF	CITATIONS
235	“Computational study of a novel catheter for liver radioembolization”. International Journal for Numerical Methods in Biomedical Engineering, 2022, , e3577.	2.1	2
236	Pure laparoscopic major liver resection after yttrium90 radioembolization: a case-matched series analysis of feasibility and outcomes. Langenbeck's Archives of Surgery, 2022, 407, 1099-1111.	1.9	2
237	In Vitro Model for Simulating Drug Delivery during Balloon-Occluded Transarterial Chemoembolization. Biology, 2021, 10, 1341.	2.8	2
238	Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.. Journal of Clinical Oncology, 2022, 40, 4074-4074.	1.6	2
239	Older age and liver transplantation. Liver Transplantation, 2005, 11, 119-119.	2.4	1
240	In Reply to Dr. Kao etÂal.. International Journal of Radiation Oncology Biology Physics, 2011, 80, 1280-1281.	0.8	1
241	Patient selection criteria for selective internal radiation therapy and integration into treatment guidelines. European Journal of Cancer, Supplement, 2012, 10, 76-80.	2.2	1
242	Dosimetry and Dose Calculation. Medical Radiology, 2013, , 53-61.	0.1	1
243	Liver function considerations for post-selective internal radiation therapy resection (hepatocellular) Tj ETQq1 1 0.784314 rgBT /Overlo	2.4	1
244	Evidence-based integration of selective internal radiation therapy into hepatocellular carcinoma management. Future Oncology, 2014, 10, 7-11.	2.4	1
245	Radioembolization as an adjunct therapy to the resection of liver tumors. Hepatic Oncology, 2015, 2, 335-338.	4.2	1
246	From the Editor's Deskâ . Journal of Hepatology, 2020, 72, 1-4.	3.7	1
247	Lymphocytes, Neutrophils and the Response to Selective Internal Radiation Therapy: More Questions than Answers Yet. CardioVascular and Interventional Radiology, 2020, 43, 1182-1183.	2.0	1
248	Immunotherapy in HCCâ”No rush despite the hype. Hepatology, 2022, 76, 906-908.	7.3	1
249	Immunotherapy in hepatocellular carcinoma. Revista Espanola De Enfermedades Digestivas, 2022, , .	0.3	1
250	How Could 90Y-Loaded Microsphere Distribution Be Optimized?. CardioVascular and Interventional Radiology, 2022, 45, 970-971.	2.0	1
251	Radioembolization-Induced Liver Disease. Medical Radiology, 2013, , 177-185.	0.1	0
252	Surgical Treatment and Radioembolization. Medical Radiology, 2013, , 167-170.	0.1	0

#	ARTICLE	IF	CITATIONS
253	Radioembolization: Concepts and Procedures. Medical Radiology, 2013, , 361-377.	0.1	0
254	Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma. , 2017, , 51-68.		0
255	Reply to: "Toxicity and dosimetry in SORAMIC study" Journal of Hepatology, 2020, 73, 735-736.	3.7	0
256	Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma. Resistance To Targeted Anti-cancer Therapeutics, 2017, , 25-43.	0.1	0
257	Dynamics in Circulating γ -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC " A Substudy From the SORAMIC Trial. , 0, 1, .		0